Vitreoscilla hemoglobin (VHb) is accumulated at high levels in both soluble and insoluble forms when expressed from its native promoter on a pUC19-derived plasmid in Escherichia coli. Examination by atomic absorption spectroscopy and electron paramagnetic resonance spectroscopy revealed that the insoluble form uniformly lacks the heme prosthetic group (apoVHb). The purified, soluble form contains heme (holoVHb) and is spectroscopically indistinguishable from holoVHb produced by VitreosciMla cells. This observation suggested that a relationship may exist between the insolubility of apoVHb and biosynthesis of heme. To examine this possibility, a series of experiments were conducted to chemically and genetically manipulate the formation and conversion of 5-aminolevulinic acid ( 
Vitreoscilla hemoglobin (VHb) is accumulated at high levels in both soluble and insoluble forms when expressed from its native promoter on a pUC19-derived plasmid in Escherichia coli. Examination by atomic absorption spectroscopy and electron paramagnetic resonance spectroscopy revealed that the insoluble form uniformly lacks the heme prosthetic group (apoVHb). The purified, soluble form contains heme (holoVHb) and is spectroscopically indistinguishable from holoVHb produced by VitreosciMla cells. This observation suggested that a relationship may exist between the insolubility of apoVHb and biosynthesis of heme. To examine this possibility, a series of experiments were conducted to chemically and genetically manipulate the formation and conversion of 5-aminolevulinic acid (ALA) Many heterologous proteins aggregate intracellularly when expressed in recombinant hosts (11, 21, 23 ). This phenomenon is best documented for protein expression in the gram-negative bacterial host Escherichia coli. However, it is not confined exclusively to this bacterium or for that matter to prokaryotic hosts (16, 25) . The mechanisms underlying this intracellular aggregation are not well understood and may vary with protein, expression construct, and host. A common theme, however, appears to be malfunction or disruption of intracellular protein folding. Mitraki and King (21) have reviewed the ways that intracellular protein folding may malfunction and lead to insolubility.
Vitreoscilla hemoglobin (VHb) is a soluble homodimeric heme protein expressed by the obligate aerobic bacterium Vitreoscilla sp. in response to low oxygen concentration (24) . This protein can be expressed from its native promoter in recombinant E. coli under similar hypoxic conditions (3, (12) (13) (14) . VHb is accumulated concurrently in both soluble and insoluble forms when expressed in E. coli from a high-copynumber pUC19-derived plasmid under the control of its native promoter (7) . The soluble form is found to partition between the cytoplasmic and periplasmic spaces despite the absence of a processed N-terminal signal peptide (15) . Similar compartmentalization is observed in the native host Vitreoscilla sp. The insoluble form accumulated in E. coli is only found aggregated in cytoplasmic inclusion bodies (7) . The principal contaminants of VHb inclusion body preparations are derived from cell wall debris which cosediment with inclusion bodies during centrifugation (7) .
In their insightful review, Mitraki and King discussed the role of cofactors in protein folding and speculated that their absence during in vivo protein folding could lead to aggregation and inclusion body formation (21 (12) . Plasmid pVSP1 was constructed from pRED2 by insertion of a 2.9-kb BamHIHindlIl fragment isolated from pJL68 (17, 18) Purified VHb exists naturally in the ferric state, presumably because of the absence of a reductase present in both Vitreoscilla sp. and E. coli (3). The Soret peak of VHb in examined samples had a maximum at 415 nm, indicating that the protein was present in the oxygenated state (22) . Soluble and insoluble VHb polypeptide levels were determined by quantitative SDS-PAGE. Heme levels were determined by the pyridine hemochromogen assay using visible difference absorption spectroscopy (4) .
Visible difference absorption spectroscopy. Samples were analyzed with a Shimadzu UV260 spectrophotometer interfaced to an IBM-XT computer. Matching 1-cm-path-length quartz microcuvettes were used with a temperature-controlled platform maintained at 25°C. Analyses were conducted in 50 mM potassium phosphate (pH 7.0). Reduced VHb was prepared by the addition of sodium dithionite. Carbon monoxidebound VHb was prepared by reduction with sodium dithionite purified VHb (5) into E. coli JM1O1::pUC19 insoluble lysate. The iron-to-polypeptide stoichiometry of the purified VHb stock was determined by amino acid analysis and atomic absorption spectroscopy to ensure that the titrated iron originated from VHb.
The membrane-normalized iron contents of E. coli JM101:: pUC19 insoluble lysate, JM1O1::pRED2 insoluble lysate, and VHb inclusion body analogs are given in Fig. 1 . Results show that purified soluble VHb contains stoichiometric levels of heme (holoVHb). This is evident because the curves indicating the iron contents of inclusion body analogs predicted from purified VHb amino acid analysis and atomic absorption spectroscopy are coincident. The experimentally determined iron content of inclusion body analogs is less than that predicted from purified VHb analysis. This is presumably caused by a reduced flow rate through the needle orifice for samples containing particulate matter. Results from analysis of JM1O1::pRED2 insoluble lysate show that the iron content is at least sixfold less than expected for lysate containing VHb with stoichiometric levels of incorporated heme. Further, the membrane-normalized iron content of JM1O1::pRED2 insoluble lysate is the same as that of JM1O1::pUC19 insoluble lysate. Each of these observations has been corroborated by electron paramagnetic resonance spectroscopy (data not shown) and shows that the insoluble form of VHb produced in JM101:: pRED2 uniformly lacks heme (apoVHb).
Perturbation of heme biosynthesis. To determine if a relationship exists between the inadequate biosynthesis of heme and insolubility of VHb in vivo, the synthesis levels of heme and VHb polypeptide were independently varied. The biosynthetic activity of heme in E. coli overexpressing VHb was perturbed by chemical and genetic means. The structure of the putative biosynthetic pathway is described in the Discussion section of this article. Because the reported rate-limiting step in heme biosynthesis in E. coli lies at synthesis of ALA, ALA availability was increased by supplementing the medium. Levulinic acid, a competitive inhibitor of ALA dehydratase, was used for specific negative perturbation of heme biosynthesis. Additionally, the gene copy number for the enzyme ALA synthase, which catalyzes the formation of ALA from gluta- limitation in the synthetic activity of porphobilinogen, the copy number of the gene for the enzyme ALA dehydratase was amplified by inserting the hemB structural gene under the control of its native promoter into the plasmid pRED2, yielding the plasmid pVDP1.
Effect of perturbations on heme accumulation. The described perturbations have various effects on heme accumulation as shown in Table 1 . High-level expression of VHb in E. coli itself leads to a dramatic increase (at least 20-fold) in the accumulation of heme, as evidenced by comparison of heme levels in cells bearing the plasmids pRED2 and pVSP1 with the heme level in cells bearing the parent plasmid pUC19. Heme levels in the former cells reach levels of 1 pumolIg (dry wt). Heme levels in cells bearing pVDP1, however, are significantly lower (approximately 0.2 times) than those in cells bearing either pRED2 or pVSP1 yet are higher than heme levels in cells bearing pUC19. This trend parallels relative VHb accumulation in these constructs (next section).
Supplementing ALA to cells bearing plasmids pUC19 and pVDP1 enhances heme accumulation. At moderate concentration (10 mM), ALA also enhances heme accumulation in pRED2; however, at higher concentrations (100 mM), it inhibits heme accumulation. ALA at all concentrations inhibits heme accumulation in cells bearing pVSP1.
Supplementing levulinic acid leads to inhibition of heme accumulation in all constructs which express VHb. Cells bearing pVSP1 are most susceptible, showing the highest inhibition at both moderate (10 mM) and high (100 mM) concentrations. A concentration of 5 mM levulinic acid is commonly used for ALA dehydratase inhibition in cell extracts from E. coli (19) . In general, cells bearing pVSP1 behave similarly when the medium is supplemented with either ALA or levulinic acid, exhibiting increased inhibition with increasing concentration.
Effect of perturbations on VHb insolubilization. Cells bearing the plasmids pRED2, pVDP1, and pVSP1 accumulate very different levels of VHb, as shown in the SDS-polyacrylamide gel in Fig. 2 . Prior to induction of the vhb promoter, the protein patterns of the soluble and insoluble fractions of the E. coli JM1O1::pRED2 (lanes 5 and 6) are very similar to those of its parent, JM1O1::pUC19 (lanes 3 and 4) . Following transfer to microaerobic conditions, JM1O1::pRED2 accumulates large quantities of both soluble and insoluble VHb (lanes 7 and 8) . By comparison, JMIOI::pVSP1 produces similar levels of VHb when induced (lanes 9 and 10) while JM1O1::pVDP1 produces much lower levels (lanes 11 and 12 1 ,umol of soluble holoVHb per g (dry wt), no soluble apoVHb, and 0.5 ,Lmol of insoluble apoVHb per g (dry wt). Both JM1O1::pVDP1 and JM1O1::pVSP1 also accumulate the majority of their VHb within 3 h of induction. Unlike JM1O1::pRED2, however, the formation of VHb species in these strains does not change significantly over the following 9 h of induction. After 12 h of cultivation, JM1O1::pVSP1 accumulates VHb to a level of approximately 1.7 ,umol/g (dry wt), but only 25% contains heme and is soluble. In JM1O1::pVDP1, VHb is accumulated to a much lower level, approximately 0.3 ,umol/g (dry wt) with an insignificant fraction being soluble and containing heme.
Response of VHb solubility to the competitive inhibitor levulinic acid is expected to be a good indicator of the sensitivity of insolubilization to heme availability. Levulinic acid supplementation does not affect the postinduction growth properties of either E. coli JMIOI::pRED2 or JM1O1::pVDP1 (data not shown). As shown in Fig. 4 under aerobic conditions (10) . As shown in Fig. 4 , adding ALA to JM101::pRED2 cultures has qualitatively the same effect as adding levulinic acid. At concentrations above 10 mM, ALA is inhibitory to holoVHb production while it has little effect on total VHb level or partitioning between soluble and insoluble forms. Adding ALA to JM101::pVDP1 at concentrations in excess of 10 mM appears inhibitory to total VHb accumulation (Fig. 5) . Results from supplementing with levulinic acid and ALA indicate that the level of holoVHb is dependent on heme levels but that the levels of insoluble apoVHb are not.
DISCUSSION
The pathway governing heme biosynthesis (Fig. 6 ) is complex and largely conserved among the plant, animal, and protista kingdoms (1) . The most notable difference in the pathway between different organisms occurs in the synthesis of ALA. Most facultative aerobic bacteria, including Vitreoscilla species (2) , synthesize ALA by the C4 pathway from succinyl coenzyme A and glycine (19) . E. coli, alternatively, synthesizes ALA by the C5 pathway from the intact five-carbon chain of glutamate (19) . The enzyme which catalyzes this transformation, ALA synthase, shows no amino acid homology with any other cloned ALA synthase (17) . Previous studies on wild-type E. coli suggest that ALA synthesis is the rate-limiting step in the heme biosynthetic pathway (8, 10) . Upon alleviating the limitation in ALA synthesis, the new limiting step may lie at porphobilinogen synthesis. ALA dehydratase, the enzyme responsible for this latter conversion, is competitively inhibited by levulinic acid (20) .
Under hypoxic conditions, Vitreoscilla cells synthesize VHb polypeptide, NADH-methemoglobin reductase and ALA synthase (2). The increase in ALA synthase levels with VHb polypeptide synthesis presumably allows the heme biosynthetic pathway to respond to the greater demand for heme. Expression of VHb in E. coli leads to increased production of heme (3, 12) . It is not known if this is accomplished by derepression of heme synthesis or by an amplification of ALA synthase levels as occurs in Vitreoscilla species.
The results described in this report suggest that ALA synthesis is not the rate-limiting step of heme biosynthesis in E. coli strains expressing high levels of VHb. This is evident since neither enhanced expression of ALA synthase or supplementing medium with ALA leads to significant increases in heme or soluble holoVHb levels. In fact, ALA supplementation resulted in decreased heme levels and ALA synthase amplification led to reduced levels of soluble holoVHb. The general similarity between these results and those observed with levulinic acid suggests that increased ALA levels actually inhibit heme synthesis in strains expressing high levels of VHb.
Spectroscopic analysis clearly shows insoluble VHb uniformly lacks heme. Perturbation of heme accumulation with analysis of VHb accumulation and solubility also shows that insolubilization is independent of heme availability. This condition is possible, because soluble VHb may or may not contain stoichiometric levels of heme, depending on the time postinduction and culture conditions. Given sufficient time, the recombinant cells can apparently synthesize sufficient heme to satisfy soluble VHb stoichiometric requirements. During this time delay, however, soluble apoVHb, which is known to be less thermodynamically stable than holoVHb (6), can be partly insolubilized. Soluble apoprotein was also observed during optimized expression of human hemoglobin in E. coli from a synthetic operon composed of a-and P-globin genes (9) .
Further research is required to determine whether these soluble apoproteins accumulate because of inadequate heme biosynthesis during high-level globin expression in recombinant E. coli.
